COLTENE Holding AG: 2026H1 Sales Approximately RMB 941 Million, Establishes Dental Joint Venture in China

Source: COLTENE 2026 First Half Results Report

COLTENE H1 2026 Net Sales of RMB 941 Million / EBIT Margin Declines to 5.1% / Gross Margin Falls to 65.0%

DentalGoodNews｜July 31, 2026 - Swiss-based COLTENE Holding AG (COLTENE) released its H1 2026 results. The report shows COLTENE achieved net sales of CHF 112.808 million (approximately RMB 941 million), down 4.4% year-on-year; on a local currency basis, net sales grew 0.8% year-on-year. Net profit stood at CHF 4.051 million (approximately RMB 33.785 million), down 5.0% year-on-year.

In terms of operating profit, COLTENE posted operating profit (EBIT) of CHF 5.753 million (approximately RMB 47.977 million) in H1, down 23.6% year-on-year, with the EBIT margin declining from 6.4% in the same period last year to 5.1%. Gross margin fell from 66.4% to 65.0%, primarily impacted by foreign exchange fluctuations, higher material and logistics costs, and changes in product mix.

Source: COLTENE 2026 First Half Results Report

By business segment, Treatment Auxiliaries generated sales of CHF 44.521 million (approximately RMB 371 million), accounting for 39.5% of total sales, down 1.5% year-on-year on a local currency basis, mainly due to inventory adjustments by a major distributor in the U.S.; Infection Control generated sales of CHF 38.684 million (approximately RMB 323 million), accounting for 34.3% of total sales, up 4.9% year-on-year on a local currency basis, with the launch of new instrument washers in the U.S. and Canadian markets serving as the primary growth driver.

Dental Preservation generated sales of CHF 29.604 million (approximately RMB 247 million), accounting for 26.2% of total sales, down 1.0% year-on-year on a local currency basis. The newly launched CanalPro CalciSeal endodontic sealer received positive feedback, while the OGSF endodontic files series continued to grow above average levels.

Source: COLTENE 2026 First Half Results Report

By region, North America remained COLTENE's largest market, generating sales of CHF 52.305 million (approximately RMB 436 million), accounting for 46.4% of total sales, down 8.3% year-on-year in Swiss franc terms and down 0.3% year-on-year on a local currency basis. North American sales were impacted by currency effects, while some Treatment Auxiliaries orders were delayed due to inventory adjustments by major distributors, with recovery expected in H2.

The Europe, Middle East and Africa (EMEA) region performed relatively strongly, generating sales of CHF 42.954 million (approximately RMB 358 million), accounting for 38.1% of total sales, up 5.5% year-on-year and up 6.8% on a local currency basis. The DACH region (Germany, Austria, and Switzerland) and the Benelux region were the main growth areas.

The Asia region generated sales of CHF 11.298 million (approximately RMB 94.225 million), accounting for 10.0% of total sales, down 13.3% year-on-year and down 7.3% on a local currency basis, primarily affected by challenging market conditions in China and the timing of certain large orders in Japan. The Latin America region generated sales of CHF 6.251 million (approximately RMB 52.133 million), accounting for 5.5% of total sales, down 13.9% year-on-year and down 9.9% on a local currency basis, mainly due to order delays caused by political uncertainty in certain markets at the beginning of the year.

Regarding its China market strategy, COLTENE established Coltene Medical Technology (Suzhou) Co., Ltd. in Changshu, China during H1, with COLTENE holding 65% of the equity and voting rights in this Joint Venture (JV). The JV focuses on the Dental Preservation segment, adopting a "local-for-local" model, with COLTENE providing technical capabilities, quality standards, and "Swiss way" expertise in dental preservation, while the Chinese partner contributes local resources, market access, and regulatory experience.

Source: COLTENE 2026 First Half Results Report

In terms of cash flow, COLTENE's Operating Cash Flow (OCF) improved from CHF 1.588 million (approximately RMB 13.244 million) in the same period last year to CHF 7.550 million (approximately RMB 62.967 million), driven primarily by improved working capital and enhanced inventory management efficiency. Free cash flow improved from CHF -0.251 million (approximately RMB -2.093 million) in the same period last year to CHF 4.808 million (approximately RMB 40.099 million).

As of June 30, 2026, COLTENE's total assets reached CHF 188.6 million (approximately RMB 1.573 billion), up 6.4% year-on-year; Shareholders' Equity stood at CHF 93.26 million (approximately RMB 778 million), representing 49.5% of total assets. Net debt at period-end was CHF 33.4 million (approximately RMB 279 million).

Looking ahead to H2, COLTENE expects market demand to gradually recover, noting that order momentum showed signs of improvement in June. For fiscal year 2026, the company expects slight sales growth and improved profitability, assuming exchange rates remain unchanged; meanwhile, the company reaffirmed its medium-to-long-term 2028 targets of 3%-5% organic sales growth and a 13%-15% EBIT margin.